Macrophage Activating Factor
GcMAF is a naturally occurring immune activating protein that converts resting immune cells into highly active macrophages, dramatically improving the body's ability to engulf pathogens, abnormal cells, and cellular debris. It is particularly relevant where chronic infections or immune suppression have blunted the innate immune response.
Product
Research shows
Practical product identifiers and format details for professional review.
Content
1.8 mg
Format
Injectable
Composition
600 mcg/ml per ml
GcMAF binds to the Gc-protein receptor on macrophage precursors (monocytes), triggering their differentiation into highly activated macrophages with enhanced phagocytic capacity and elevated superoxide production. Activated macrophages demonstrate significantly increased ability to engulf and destroy pathogens, malignant cells, and immune complexes. GcMAF also stimulates natural killer cell activity, promotes dendritic cell maturation, and indirectly enhances T and B lymphocyte function. Research has shown that GcMAF administration can overcome the immunosuppressive mechanisms deployed by chronic infections and certain tumour microenvironments.
Based on published research and preclinical data. All benefits are documented under research-grade conditions.
GcMAF converts monocytes into highly activated macrophages with dramatically increased phagocytic capacity. These activated macrophages demonstrate 5–10x greater ability to engulf and destroy pathogens, tumour cells, and cellular debris compared to resting macrophages.
Many cancers produce Nagalase: an enzyme that degrades Gc-protein, reducing the body's ability to produce endogenous GcMAF and effectively suppressing macrophage activation in the tumour microenvironment. Exogenous GcMAF bypasses this immunosuppressive mechanism.
GcMAF stimulates NK cell activity and cytotoxic function: providing a second immune cell type with enhanced tumour-surveillance capability alongside the activated macrophage population.
Enhanced macrophage activation improves the speed and completeness of response to viral and bacterial infections. GcMAF research has documented benefits in chronic viral conditions, including HBV and Lyme disease co-conditions in clinical case series.
GcMAF promotes dendritic cell differentiation and maturation, improving antigen presentation capacity and the quality of the adaptive immune response generated against new antigens: relevant for vaccine responsiveness and novel pathogen encounters.
In conditions of immune suppression (post-viral fatigue, immunosenescence, or chronic infection), GcMAF provides direct activation rather than merely modulating an already-compromised system: bypassing the downstream failures that limit other immune support approaches.
Explore selected publications and registered trials on GcMAF, with links to the original sources.
5 publications from the research library.
Evidence type
Publication and key finding
Source
Evidence type
Published research
GcMAF mechanism review
Publication and key finding
The study reports that the protein is believed to exhibit a wide range of therapeutic properties associated with the activation of macrophagal immunity.
International journal of molecular sciences
Evidence type
Preclinical study
GcMAF angiogenesis evidence
Publication and key finding
The study reports that fGF-2-induced neovascularization in murine cornea was also inhibited by GcMAF.
Journal of the National Cancer Institute
Evidence type
Published research
GcMAF preclinical neuroprotection evidence
Publication and key finding
The study reports that oxaliplatin-based regimens are effective in metastasized advanced cancers.
Anti-cancer drugs
Evidence type
Published research
Direct GcMAF evidence
Publication and key finding
The study reports that gcMAF increased macrophage tumoricidal activity but TNF and NO release were not involved in the mechanism.
Anticancer research
Evidence type
Published research
Direct GcMAF evidence
Publication and key finding
The study reports that these preliminary data are important for designing small molecular GcMAF mimics.
Anticancer research
2 selected studies from the wider trial library, in the order chosen for this product.
NCT06877364
NCT06434077
Labbieux pens are designed for 30 to 31 administrations of 10 clicks. With daily use, this corresponds to approximately one month. We recommend starting with 5 clicks and building up to 10 clicks per administration. More sensitive people may use fewer clicks.
Before using our pens, consult the manual.
GcMAF has a generally favourable safety profile in published case series and small clinical reports. The most commonly reported effects are immune activation responses: mild fever, fatigue, or flu-like symptoms in the first few days, consistent with acute macrophage activation. These typically resolve with dose reduction or temporary pause. Because GcMAF is an immune activator, it should be used with caution in individuals with autoimmune conditions: macrophage activation may amplify the inflammatory component of autoimmune disease. Injection site reactions are uncommon. The product requires careful cold-chain handling as it is a glycoprotein that degrades rapidly above appropriate storage temperatures.
Other products from the same range
